Audit of clinical practice in the use of incretin mimetic agents for the management of patients with type 2 diabetes

Practical Diabetes

Volumn 30, Issue 4, 2013, Pages 159-162

  Dhesi, Balraj ^a   Chauhan, Hiren ^a   Basu, Ansu ^a,b  

^a CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

DPP 4; GLP 1; Incretin mimetics

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INCRETIN; INSULIN; LIRAGLUTIDE; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL PRACTICE; FEMALE; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; WEIGHT REDUCTION;

EID: 84881349333     PISSN: None     EISSN: 20472900     Source Type: Journal    
DOI: 10.1002/pdi.1767     Document Type: Article

References (17)

1. Drucker D, Nauck M. The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705.
2. Creutzfeldt W, Nauck M. Gut hormones and diabetes mellitus. Diabetes Metab Rev 1992;8: 149-77.
3. Nauck M, et al. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993;76:912-7.
4. Nauck M, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91:301-7.
5. Visboll T, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50:609-13.
6. Nauck M, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52.
7. National Institute for Health and Clinical Excellence. Type 2 diabetes - newer agents (partial update of CG66) (CG87). May 2009. http://publications. nice. org.uk/type-2-diabetes-cg87 [accessed May 2012].
8. National Institute for Health and Clinical Excellence. Diabetes (type 2) - liraglutide (TA203) October 2010. http://publications.nice.org.uk/liraglutide- forthe- treatment-of-type-2-diabetes-mellitus-ta203 [accessed May 2012].
9. Ryder REJ, et al. The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Pract Diabetes Int 2010;27:352-7b.
10. Thong K, et al. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit. Diabetes Obes Metab 2011; 13:703-10.
11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
12. Kahn SE, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
13. UK Prospective Diabetes Study (UKPDS) Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58.
14. Meir JJ. Beta cell mass in diabetes: a realistic therapeutic target? Diabetologia 2008;51:703-13.
15. Amori RE, et al. Efficacy and safety of incretin therapy in type 2 diabetes. JAMA 2007;298:194-206.
16. Zander M, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359:824-30.
17. Kielgast U, et al. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 2011;34:1463-8.